Mitochon Pharmaceuticals: Channeling the Ability of Mitochondria to Create Resilient, Protective Cells in Neurodegeneration and Aging
The thesis of Mitochon’s approach is that if you bolster mitochondrial health through a mechanism known as mitochondrial uncoupling, meaningful pro-survival benefits occur and brain cells are protected from damaging disease processes.
Dr. John G. Geisler’s post-doctoral work at Pfizer and Yale University in metabolic disease, taught him that there are master switches (proteins to target with medicines) that can have a profound effect on disease progression. This knowledge became the theme of his subsequent work in drug discovery working at the roots of problems. By removing fat from the liver and muscle cells that cause insulin resistance, the aim was to wean individuals off the insulin and cure their diabetes.